131053Feasibility assessment of a novel vaccine platform for the stratified therapeutic vaccine intervention in non-small cell lung cancer.ClosedFeasibility StudiesInnovate UKOne in three of us will be affected by cancer during our lifetimes. Given the ever increasing burden of disease and an ageing population, the costs of providing optimal care in Britain alone will rise by a staggering 62% over the next decade. Current healthcare models and practices are unsustainable. Immune Targeting Systems Ltd is a London based Biotechnology Company developing innovative vaccines technologies against for mutating viruses (influenza and hepatitis-B) and is now extending the platform pipeline into oncology, initially in non-small cell lung cancer. This project is the first stage of this new investment through feasibility assessment of the use of an in vitro assay as a stratification tool for cancer vaccines peptide antigens: (1) to select tumour associated antigen derived long peptides for vaccine inclusion, and (2) to select patients suitable for vaccine intervention. Thereby providing a clear clinical development plan for a novel stratified therapeutic oncology vaccine.